| Unique ID issued by UMIN | UMIN000063708 |
|---|---|
| Receipt number | R000072807 |
| Scientific Title | Study Evaluating the Effects of a Test Food on Sleep --A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Trial-- |
| Date of disclosure of the study information | 2026/11/20 |
| Last modified on | 2026/11/17 17:39:33 |
Study Evaluating the Effects of a Test Food on Sleep
--A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Trial--
Study Evaluating the Effects of a Test Food on Sleep
Study Evaluating the Effects of a Test Food on Sleep
--A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Trial--
Study Evaluating the Effects of a Test Food on Sleep
| Japan |
No
| Not applicable | Adult |
Others
NO
The purpose of this study is to evaluate the effects of short-term consumption of the test food on subjective sleep status and daytime functioning.
Efficacy
OSA Sleep Inventory (MA Version)
Japanese Version of the Epworth Sleepiness Scale (JESS)
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Prevention
| Food |
Oral intake of the test food (2 tablets per day for 11 days)
Oral intake of the placebo food (2 tablets per day for 11 days)
| 20 | years-old | <= |
| 60 | years-old | > |
Male and Female
This study is open to individuals who meet all of the following criteria:
1) Men and women aged 20 or older but under 60 at the time of obtaining consent to participate in the study.
2) Healthy individuals with no chronic medical conditions.
3) Individuals who are dissatisfied with the quality of their sleep (e.g., reduced daytime performance, severe daytime sleepiness, difficulty falling asleep, shallow sleep, difficulty waking up, etc.) .
4) Individuals whose work schedule generally consists of daytime shifts five days a week, with Saturdays and Sundays as days off.
5) Individuals who have received a thorough explanation of the purpose and content of this trial, have understood it, and have consented in writing to participate in the trial of their own free will.
6) Individuals who are able to visit the facility on the designated examination date and undergo the prescribed examinations.
7) Individuals whom the principal investigator deems appropriate to participate in this trial.
Any individual who meets any of the following criteria will be excluded from this study.
Individuals
1) w with chronic diseases or undergoing treatment for any illness.
2) with suspected SAS or current or past treatment for SAS.
3) with suspected or confirmed nocturia, benign prostatic hyperplasia, or overactive bladder.
4) with current or past chronic fatigue syndrome, mental or sleep disorders, hypertension, diabetes, dyslipidemia, or other serious diseases.
5) with current or past serious liver, kidney, heart, lung, blood, or digestive diseases.
6) with severe anemia.
7) regularly using oral or topical medications for illness within the past month.
8) with a BMI of 30.0 kg/m2 or higher.
9) at risk of allergies to test food ingredients, other foods, or drugs.
10) regularly using sleep-related health foods or supplements now or in the past 3 months, or planning to use them during the study.
11) regularly using supplements or probiotics mainly containing lactic acid bacteria or bifidobacteria.
12) who regularly consume alcohol.
13) who regularly consume 400 mg or more of caffeine per day.
14) with irregular bedtimes or wake-up times, or routinely sleeping less than 4 hours after going to bed at or after midnight.
15) unable to sleep alone or whose sleep may be disturbed by children, pets, etc.
16) at risk of dermatitis from EEG electrode pads, including those with adhesive-related dermatitis history.
17) planning changes in daily routines or sleeping environments due to travel or other reasons during the study.
18) currently in another clinical trial or within 3 months of its completion.
19) who are pregnant, breastfeeding, may be pregnant, or intend to become pregnant during the trial period.
20) Any other individuals whom the principal investigator deems ineligible for this trial.
70
| 1st name | Tatsuhiko |
| Middle name | |
| Last name | Hirota |
Asahi Quality & Innovations, Ltd.
Core Technology Research Institute
302-0106
1-21,Midori 1-chome,Moriya-shi,Ibaraki,302-0106
0297-46-1111
tatsuhiko.hirota@asahi-qi.co.jp
| 1st name | Ryoma |
| Middle name | |
| Last name | Shimizu |
TES Holdings Co., Ltd.
Administrative Department of Clinical Trials
110-0015
6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN
+81-3-6801-8480
r.shimizu@tes-h.co.jp
TES Holdings Co., Ltd.
Asahi Quality & Innovations, Ltd.
Profit organization
Ueno-Asagao Clinic Ethical Review Committee
6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN
+81-3-6240-1162
jimukyoku@tes-h.co.jp
NO
| 2026 | Year | 11 | Month | 20 | Day |
Unpublished
Preinitiation
| 2026 | Year | 11 | Month | 11 | Day |
| 2026 | Year | 11 | Month | 12 | Day |
| 2026 | Year | 12 | Month | 01 | Day |
| 2026 | Year | 12 | Month | 26 | Day |
| 2026 | Year | 11 | Month | 20 | Day |
| 2026 | Year | 11 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072807